A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 255 participants.

Also called NCT05687890

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 255 participants (enrolled count) (from the registry)
Sponsor
Biocity Biopharmaceutics Co., Ltd. (from the registry)
Registry
  • NCT NCT05687890
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05687890. Randomized; double masking; primary purpose treatment. Start 2023-05-23 (actual); primary completion 2024-11-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease
Condition
Diabetic Kidney Disease
Condition
IgA Nephropathy
Intervention (Drug)
Placebo of SC0062
Intervention (Drug)
SC0062 low dose
Intervention (Drug)
SC0062 medium dose
Intervention (Drug)
SC0062 high dose
Lead sponsor
Biocity Biopharmaceutics Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05687890
Content hash
a6f16ed3059355b1c84f80a14ac6a8c28353190faaa85cc3e3936fbfa4669760